5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) is an entactogenic designer drug which is a methamphetamine derivative structurally related to 5-APB and MDMA. It has similar effects to these drugs in humans and has been used as a recreational drug. 5-MAPB was temporarily banned in the UK in June 2013 after being detected being used as a street drug and sold online, along with 9 other related compounds.
§Legality
5-MAPB is not itself listed in the CDSA but since it's an amphetamine and analog thereof it would be considered illegal in Canada.
5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order. On March 5, 2014 the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.
§Metabolism and toxicity
Little formal knowledge exists on 5-MAPB. User reports suggest effects similar to MDMA, 5-MAPB shares structural relation to MDMA, however it is unlikely to produce the metabolite speculated by some to be the major factor in the neurotoxicity of MDMA; 2,5-bis-(glutathion-S-yl)-alpha-methyldopamine or the major psychedelic metabolite MDA. A study in rats indicated that the major metabolites of 5-MAPB are 5-APB and 3-carboxymethyl-4-hydroxymethamphetamine.
§See also
- 5-EAPB
- 5-APDB
- 5-MAPDB
- 5-API
- 6-MAPB